# Ocean Biomedical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Ocean Biomedical, Inc.). ## Overview Ocean Biomedical, Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing drug candidates in oncology, fibrosis, and infectious disease. Its business centers on advancing preclinical and clinical-stage programs, protecting intellectual property, and, if successful, moving candidates through regulatory approval toward commercialization or licensing. ## Products & services • Preclinical drug discovery and development • Clinical-stage therapeutic programs • Drug manufacturing process development • Regulatory approval and commercialization planning • Intellectual property licensing and protection - **Preclinical programs** (40%) — Discovery-stage therapeutic assets being advanced through research and early development. - **Clinical-stage programs** (35%) — Drug candidates in human trials across oncology, fibrosis, and infectious disease. - **Manufacturing and process development** (10%) — Work to produce drug material and prepare late-stage and commercial manufacturing processes. - **Licensing and partnering** (10%) — Potential out-licensing or collaboration structures tied to product candidates and IP. - **Intellectual property portfolio** (5%) — Patent and know-how assets supporting candidate development and partnering value. - Preclinical drug discovery and development - Clinical-stage therapeutic programs - Drug manufacturing process development - Regulatory approval and commercialization planning - Intellectual property licensing and protection ## Customers Ocean Biomedical does not currently sell commercial products, so its near-term counterparties are research institutions, contract manufacturers, clinical service providers, and potential licensing partners. If product candidates are approved, the company would ultimately serve physicians, hospitals, and other healthcare providers through commercial drug sales or partners. The business model also depends on universities and medical centers that contribute research assets and scientific collaboration. - **Research universities and medical centers** (primary) — Provide licensed discoveries, scientific collaboration, and translational research support. - **Contract development and manufacturing organizations** (primary) — Manufacture preclinical and clinical drug material and support process development. - **Clinical research ecosystem** (primary) — Trial sites, CROs, and service providers that execute preclinical and clinical studies. - **Potential licensing and commercialization partners** (secondary) — Pharmaceutical partners that may license assets or help commercialize approved products. - **Future healthcare providers and patients** (emerging) — End users of approved therapies in oncology, fibrosis, or infectious disease. - Research universities and medical centers that support licensing partnerships - Contract manufacturers and CMOs that produce preclinical and clinical material - Clinical trial vendors and service providers that support development work - Potential pharmaceutical partners or licensees for approved or partnered assets - Future healthcare providers and patients if products reach commercialization ## Geography Ocean Biomedical is headquartered in the United States and operates as a U.S. public biotechnology company. Its development work is organized around research, clinical development, manufacturing, and regulatory activities that may involve U.S.-based and global third-party partners, but no country-level revenue is disclosed because the company has not generated product revenue. - Headquartered in the United States - Primary operating footprint is U.S.-based research and corporate activity - Clinical and manufacturing partners may be located outside the company - No product revenue disclosed, so no country revenue mix is available ## Strategy The company’s strategy is to advance a pipeline of oncology, fibrosis, and infectious disease candidates from preclinical work into clinical testing and, if successful, through regulatory approval. It also aims to build manufacturing, commercialization, and intellectual property capabilities so it can either launch products itself or monetize assets through licensing partnerships. - **Advance pipeline candidates into the clinic** (short-term) — Clinical entry is the key value-creation step for a pre-commercial biotech company. - **Secure regulatory approvals** (medium-term) — Approval is required before any candidate can be sold or broadly commercialized. - **Build manufacturing and commercialization capability** (medium-term) — Late-stage development requires reliable supply and a path to market. - **Protect and expand intellectual property** (long-term) — Patent protection supports partnering leverage and future exclusivity. - Advance preclinical assets into clinical development - Obtain regulatory approvals for product candidates - Build manufacturing and commercialization readiness - Expand intellectual property protection around the pipeline - Use licensing partnerships to extend reach and reduce execution burden ## Risks Ocean Biomedical faces the typical risks of an early-stage biotechnology company: its candidates may fail in preclinical or clinical development, regulatory approval may not be obtained, and commercialization may never occur. The company also carries meaningful financing and dilution risk because development, manufacturing, and regulatory work require substantial capital before any product revenue is generated. - **Clinical and development failure** [high] — Therapeutic candidates must succeed through preclinical and clinical testing before approval. - **Regulatory approval risk** [high] — Even promising candidates require successful regulatory review before commercialization. - **Financing and liquidity risk** [critical] — The company has no product revenue and depends on external capital to fund operations. - **Debt and dilution risk** [high] — Outstanding convertible notes and warrants can pressure cash needs and share count. - **Intellectual property risk** [medium] — Value depends on obtaining and protecting patents and licensed rights. - Drug candidates may fail in preclinical or clinical testing - Regulatory approval may be delayed or denied - Additional capital may be unavailable when needed - Debt service and refinancing needs may strain liquidity - Intellectual property may be difficult to obtain or defend - Commercial launch risk remains high if products are approved ## Accounting The most important accounting judgments are valuation of complex financing instruments, including convertible notes, warrants, and the backstop put option liability. Because the company is pre-revenue, investors should also watch how research and development costs are expensed, how accrued expenses are estimated, and whether any future intangible or goodwill balances become subject to impairment testing. - **Convertible notes and warrants** — Can materially affect liabilities, equity, and reported earnings - **Backstop put option liability** — May create volatility in other income/expense - **Research and development expense recognition** — Drives reported burn and comparability across periods - **Accrued expenses and external service estimates** — Can shift expenses between periods - Fair value measurement of convertible notes and warrants - Valuation of backstop put option liability and related financing items - Accrual estimates for external development, legal, and accounting costs - Immediate expensing of research and development costs - Potential impairment of acquired intangibles or goodwill if present --- *Last updated: 2026-04-29T04:43:31.418848+00:00*